Pegloticase: A new biologic for treating advanced gout

Herbert S B Baraf, Alan K. Matsumoto

Research output: Contribution to journalArticle

Abstract

Although pharmacologic therapies for hyperuricemia in patients with gout have been well established and are reasonably effective, a small proportion of patients are refractory to treatment and/or present with articular disease so severe as to render standard treatments inadequate. Pegloticase, a PEGylated mammalian urate oxidase with a novel mechanism of action, was recently approved in the USA for the treatment of chronic gout in adult patients refractory to conventional therapy. This paper outlines the development of this unique agent and provides details of the Phase III clinical trial program. A discussion of patient selection, treatment considerations, and risk management for infused pegloticase follows. As a new class of biologic agent offering documented and dramatic effects on lowering serum uric acid and remarkably rapid outcomes in resolving tophi, pegloticase can provide safe and effective management of hyperuricemia and gout for many patients, particularly those who have a high disease burden or who have previously failed to respond to other therapies.

Original languageEnglish (US)
Pages (from-to)143-154
Number of pages12
JournalInternational Journal of Clinical Rheumatology
Volume7
Issue number2
DOIs
Publication statusPublished - Apr 2012
Externally publishedYes

    Fingerprint

Keywords

  • biologic therapy
  • chronic gout
  • hyperuricemia
  • pegloticase

ASJC Scopus subject areas

  • Rheumatology

Cite this